84-1031-15　Plasminogen Activator Inhibitor Type 1 (PAI 1) 500ul　P4256-31

特徴

• The cardiovascular risk factor plasminogen activator inhibitor type 1 (PAI 1) has been associated with abdominal obesity, hypertension, hypertriglyceridemia, hyperinsulinemia, glucose intolerance, and type II diabetes, conditions known to be linked with insulin resistance.
• Plasminogen activator inhibitor 1 (PAI 1) is a member of the serine protease inhibitor (serpin) superfamily and a central regulatory protein in the blood coagulation system.
• PAI-1 is unique among serpins in exhibiting distinct active and inactive (latent) conformations in vivo.
• Human PAI 1 is a single-chain glycoprotein with a molecular weight of 43kD.
• This inhibitor acts as “bait” for tissue-type and urokinase-type plasminogen activators (tPA and uPA) and protein C.
• Its rapid interaction with tPA may function as a major control point in the regulation of fibrinolysis.
• The highly mobile reactive-center loop (RCL) is thought to account for both the rapid inhibiton of plasminogen activators, and the rapid and spontaneous transition of the unstable, active form of PAI 1 into the stable, inactive conformation.
• The inactive form can be partially reactivated by denaturants such as urea, guanidine hydrochloride or SDS.
• High concentrations of PAI 1 have been associated with human thromboembolic disease.
• PAI 1 activity may limit the extent of tumor metastasis, since uPA activity is a major contributory factor promoting dissolution of tumor matrix and basement membrane.
• Applications:Suitable for use in Immunoelectrophoresis (IEP) and ELISA.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.